BrainsWay Ltd.(BWAY)Earnings, Financials & Key RatiosBrainsWay Ltd. (BWAY) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company demonstrates strong top-line growth of 34.6% and a solid $58.6M cash position, the erratic cash conversion and reliance on interest income for net profitability warrant a cautious wait-and-see approach.
BrainsWay Ltd. (BWAY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
BrainsWay Ltd. (BWAY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.12vs $0.05+140.0% | $16Mvs $15M+6.1% |
| Q2 2026 | Mar 11, 2026 | $0.14vs $0.06+133.3% | $15Mvs $14M+3.8% |
| Q4 2025 | Nov 11, 2025 | $0.08vs $0.11-27.3% | $14Mvs $14M-3.6% |
| Q4 2025 | Sep 30, 2025 | $0.05 | $13M |
Recent stock market news and headlines for BrainsWay Ltd. (BWAY)
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 million members in South Carolina allowing for coverage of SWIFT, in addition to various other increases in Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) patients.
Key metrics vs top competitors for BrainsWay Ltd. (BWAY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.02 | $628.35M | 44.50 | 27.33% | 14.62% | 11.26% | — | |
| $1.35 | $93.94M | -2.29 | 99.17% | -24.48% | -139.83% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $84.03 | $4.62B | -18.88 | 10.74% | 7.47% | 9.13% | — | |
| $148.70 | $8.7B | -45.34 | 32.33% | -34.34% | -26.46% | — | |
| $46.31 | $383.45M | 53.85 | 16.97% | 14.08% | 22.14% | — |
BrainsWay Ltd. (BWAY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BWAY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BrainsWay Ltd. (BWAY) stock FAQ — growth, dividends, profitability & financials explained
BrainsWay Ltd. (BWAY) reported $56.2M in revenue for fiscal year 2025. This represents a 15334% increase from $0.4M in 2012.
BrainsWay Ltd. (BWAY) grew revenue by 27.3% over the past year. This is strong growth.
Yes, BrainsWay Ltd. (BWAY) is profitable, generating $8.8M in net income for fiscal year 2025 (14.6% net margin).
BrainsWay Ltd. (BWAY) has a return on equity (ROE) of 11.3%. This is reasonable for most industries.
BrainsWay Ltd. (BWAY) generated $12.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
